Recent Updates
Recently added Catalysts

HER2 Positive Breast Cancer: two biotech companies racing to a treatment

OncologyConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$10.2Buniverse median $1.20B
Allocated capital$3.3B$20.4B competing
Phase 3 or filed01 mid, 1 early
Pure plays0this indication only
Capital rank60/299crowding rank 78

HER2 Positive Breast Cancer is a two-horse race: Jazz Pharmaceuticals (JAZZ, $16.1B) against Enliven Therapeutics (ELVN, $4.4B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $3.3B of allocated capital sits on the pair.

JAZZ alone accounts for 79% of the $20.4B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$3.3B of allocated capital sits in HER2 Positive Breast Cancer, ranking it 60th of 299 indications by the money committed to it.

Companies developing drugs for HER2 Positive Breast Cancer 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
JAZZJazz PharmaceuticalsZanidatamabPhase 22$16.1BNo14 30 Sep 2026
ELVNEnliven TherapeuticsELVN-002Phase 11$4.4BNo2 9 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. JAZZ holds 79% of the $20.4B competing in this indication.

Why HER2 Positive Breast Cancer is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. HER2 Positive Breast Cancer has 2 competitors and a median of $10.2B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Bladder Cancer with FGFR3 Mutation1 company · $3.3B · median $6.6BUncontestedRenal Cell Carcinoma5 companies · $3.4B · median $3.8BConcentrated betGastric Cancer8 companies · $3.6B · median $575MKnife fightChronic Lymphocytic Leukemia4 companies · $3.7B · median $2.1BConcentrated betGlioblastoma6 companies · $3.0B · median $432MKnife fightMetastatic Castration Resistant Prostate Cancer3 companies · $2.8B · median $4.0BConcentrated betNon-Squamous Non-Small Cell Lung Cancer1 company · $2.7B · median $13.7BUncontestedProstate Cancer6 companies · $2.7B · median $1.1BKnife fight

HER2 Positive Breast Cancer pipeline questions

Which biotech companies are developing drugs for HER2 Positive Breast Cancer?

Jazz Pharmaceuticals (JAZZ, Zanidatamab, Phase 2); Enliven Therapeutics (ELVN, ELVN-002, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in HER2 Positive Breast Cancer.

How advanced is the HER2 Positive Breast Cancer pipeline?

Of the 2 clinical-stage programmes in HER2 Positive Breast Cancer, 0 are in Phase 3 or filed, 1 is in mid-stage development and 1 is in early-stage development.

Which company leads the HER2 Positive Breast Cancer field?

JAZZ is the largest developer in HER2 Positive Breast Cancer, holding 79% of the $20.4B of market capitalisation competing in the indication. The median competitor is worth $10.2B.

When is the next HER2 Positive Breast Cancer catalyst?

The next dated catalyst in HER2 Positive Breast Cancer is ELVN on 9 Sep 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map